Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 564

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1B
Chunk 564
---
 D.C. Mr. Lee is well qualified to serve as Lead Director because
of his membership in the New York State Bar and extensive experience in both legal and investment sectors across various asset classes,
demonstrating significant expertise in capital markets.

Dr. Alcide Barberis has been a Director of the Company as
of the Closing of the Business Combination. He is a biotech entrepreneur, Board Member and Executive with over 25 years of
management experience in the biotechnology industry, and scientific experience in the private and public research sectors. He is
currently CEO & Director of Mabylon AG (since 2017). Before joining Mabylon, he was CEO & President of Humabs
BioMed, now a subsidiary of VIR Biotechnology (2013-2016). His career has included senior positions at entrepreneurial startups
(Co-Founder of ESBATech AG (1998) and Oncalis AG (2006) and senior Executive Management, R&D Management
and Business Development positions. He has been member of the Board of Directors of ESBATech (now a Novartis company, 1998-2004),
Oncalis (2006-2012) and EffRx Pharmaceuticals (2016-2023), and he is currently (since March 2023) on the
Board of Directors of Ontrack Biomedical. From 2016 through 2021 he was also Coordinator of the Startup Promotion Center of the
University of Svizzera Italiana in Lugano, Switzerland. Dr. Barberis earned a PhD in Molecular Biology and Biochemistry from
the University of Zürich (1988). Dr. Barberis is well qualified to serve as a Director because of his extensive management
and leadership experience in the biotech industry, startup companies, and in the private and public scientific research sectors.

95

Dr. Seng Chin Mah became a Director of the Company as of the
Closing of the Business Combination. Dr. Mah has been Chairman of the Board of BioVersys AG since 2009. He was previously Chief
Executive Officer of the Canyon Pharmaceuticals Group AG (2009-2021) and has over 30 years’ experience in the pharma and biotech
industry. Prior to Canyon Pharmaceuticals, he was Head of Development of the Integration Office during the integration of Chiron into
Novartis (2005-2008) and held other positions at Novartis